
Issues presented are just some of the larger healthcare challenges that have dogged the nation for decades.
It was preparing to defend itself at trial last month against allegations that its abuse of market power inflated California healthcare costs by $400 million, but non-profit healthcare system Sutter Health agreed to resolve the class action brought in 2012 by individuals and businesses. Plaintiffs charged the state’s second largest healthcare system with illegal tying and exclusive dealing which prevented plans from steering patients to lower-cost providers (Sidibe v. Sutter Health, No. 12-cv-04854-LB, N.D. Calif.).
This is a reversal of fortune for Sutter. In 2022, the Ninth Circuit overturned a jury verdict in favor of the company, saying the trial judge erred by incorrectly instructing the jury and by excluding relevant evidence (Sidibe v. Sutter Health, No. 22-15634, 9th Cir.).
The appellate court said the trial judge should not have removed the word “purpose” from the Judicial Council of California Civil Jury Instructions. The judge should have directed jurors to consider the “anticompetitive purpose” of Sutter’s conduct which is an essential aspect of the rule of reason analysis under both the Cartwright Act and the Sherman Act, said the Ninth Circuit. Further, the trial court abused its discretion under Federal Rule of Evidence 403 by excluding as “minimally relevant” details of Sutter’s pre-2006 conduct. The evidence concerned the company’s stated purpose and the effects of its conduct.
The second trial was to begin on March 2, but Sutter Health agreed to resolve the case by paying an undisclosed amount, conceding to provisions intended to prevent anticompetitive practices, and agreeing to conduct its operations with transparency.
This is not Sutter Health’s first major settlement in California this decade. In August 2021 the state Superior Court in San Francisco approved a $575 million settlement with the company. That agreement resolved allegations by the state Attorney General’s office, the United Food and Commercial Workers and Employers Benefit Trust, and class action plaintiffs that Sutter’s anticompetitive practices raised healthcare costs for consumers in Northern California compared to other parts of the state.
Similar to its recent settlement, the company was prohibited from further anticompetitive conduct and agreed to follow certain practices to restore competition (UFCW & Employers Benefit Trust v. Sutter Health, et al., Case No. CSG 14-538451, Superior Court of the State of California, City and County of San Francisco).
California Healthcare Market
In 2023, Sutter Health reported total revenues of $16.13 billion, making it a distant second to Kaiser Permanente, the highest-earning healthcare system in the state which has also faced antitrust allegations in the past. The top healthcare providers and hospital chains in California generate an estimated $145.4 billion annually. They are:
| Health System | Revenue |
| Kaiser Permanente | $93 billion |
| Sutter Health | $16.13 billion |
| Stanford Health Care | $6.76 billion |
| Dignity Health | $6.7 billion |
| UCSF Health | $6.15 billion |
| Cedars-Sinai Health | $4.34 billion |
| UC Davis Health | $3.61 billion |
| Sharp HealthCare | $3.5 billion |
| UC San Diego Health | $3.06 billion |
| UCLA Health | $2.86 billion |
Costs and Concentration
In 2022, U.S. healthcare spending increased by 4.1% to $4.5 trillion, or $13,493 per capita, according to the American Medical Association. This growth rate is comparable to pre-pandemic levels. Spending on prescription drugs grew by 8.4% in 2022, driven by higher prices and increased utilization, the AMA found.
Tactics like those allegedly exercised by Sutter Health are just a couple examples of what is driving healthcare costs upward. Labor shortages, higher wages, rising supply costs, utilization of behavioral health services, and policy changes at the federal level are other factors contributing to rising costs, adversely affecting providers and consumers.
Another factor driving prices is the increasing concentration of the healthcare industry, in part fueled by private equity acquisitions.
According to a study published in Health Affairs, healthcare markets became increasingly concentrated between 2010 and 2016. By 2016, 90% of all metropolitan areas had highly concentrated hospital markets, 65% had highly concentrated specialist physician markets, 39% had highly concentrated primary care physician markets, and 57% had highly concentrated insurance markets.
The Commonwealth Fund commented that while increased concentration is associated with higher healthcare prices, it is not associated with improvements in quality of care.
The Government Accountability Office found that the individual health insurance market became more concentrated from 2011 through 2022, with 47 states having concentrated markets at its peak in 2019.
Increased concentration, higher prices, and questions about the quality of care necessitate attention from antitrust law enforcers. The Biden and Trump administrations each recognized this but had different views on causation and solutions.
Healthcare prices, market consolidation, and the role of private equity in consolidation were concerns of the Biden White House, which directed the Department of Justice, Federal Trade Commission and the Department of Health and Human Services to examine the role of private equity in the competitive health of the healthcare sector. They were to work together to identify potentially anticompetitive roll-up transactions, and they actively pursued alleged anticompetitive activity and mergers.
Under the new leadership of Assistant Attorney General Gail Slater, the Antitrust Division has also shared concerns about market concentration in various industries, but from a different perspective.
A statement from the Division says some of the blame belongs to government agencies and their enforcement of “anticompetitive state and federal laws and regulations that undermine free market competition and harm consumers, workers, and businesses.”
Laws and regulations in healthcare markets are among the targets for scrutiny, because they “too often discourage doctors and hospitals from providing low-cost, high-quality healthcare and instead encourage overbilling and consolidation,” according to a March 27 statement on the DOJ website, which adds, “These kinds of unnecessary anticompetitive regulations put affordable healthcare out of reach for millions of American families.” Regulations governing food and agriculture, energy, housing, and transportation can also expect scrutiny.
The Trump administration’s FTC, although the term is young, has acted to promote competition in the healthcare space in a couple of instances. On March 17, it urged the Indiana Department of Health to deny Union Hospital, Inc. and Terre Haute Regional Hospital, L.P.’s application to merge. This is their second attempt to merge under a proposed “certificate of public advantage” (COPA). The first time was during the Biden administration, which also flagged the deal as anticompetitive. The second attempt presents the same anticompetitive harms as the first, the FTC said. Shielded by a COPA from antitrust scrutiny, the merger would drive up healthcare costs for patients and lower wages for hospital workers, according to the agency.
The FTC also recently sued to block as anticompetitive GTCR BC Holdings, LLC’s purchase of Surmodics, Inc. The deal would combine the two largest manufacturers of critical medical device coatings used in devices such as neurovascular catheters and guidewires.
Conclusion
The challenges facing the healthcare industry and healthcare consumers are multifaceted, involving rising costs, concentration of markets, and evolving regulatory frameworks. Both recent administrations have acknowledged these issues, albeit with differing views and approaches, making it clear that addressing healthcare prices and maintaining competitive markets will require vigilance and collaboration among agencies, institutions, companies, legislators, regulators, and others, an environment that has eluded us for many years in the healthcare arena.
______________
Contact Mogin Law LLP
Attorneys, if you wish to speak to us about a legal matter, write to us at Info@MoginLawLLP.com. Editors, if you have a question about this post or other antitrust topics, write to us at Media@MoginLawLLP.com. We can also be reached at 619.687.6611.